SCHEMBL18532192

SCHEMBL18532192

CSC1CCN(C(=O)C(C)C)CC1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
KMT2A Q03164 1/20 0.44
CHRNB2 P17787 1/20 0.41
CHRNA3 P32297 1/20 0.41
CHRNA4 P43681 1/20 0.41
CHRNB3 Q05901 1/20 0.41
CHRNA6 Q15825 1/20 0.41
FAAH O00519 1/20 0.38
EPHX2 P34913 4/20 0.38
NAMPT P43490 1/20 0.37
HRH3 Q9Y5N1 2/20 0.35
CYP2D6 P10635 1/20 0.35
KCNH2 Q12809 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
NPY5R Q15761 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20635825 0.82 MEN1 (0.43) MEN1ALDH1A1KMT2ACHRNB2CHRNA3
SCHEMBL22874730 0.79 MEN1 (0.38) MEN1ALDH1A1KMT2AEPHX2
SCHEMBL2739929 0.77 MEN1 (0.48) MEN1ALDH1A1KMT2ACHRNB2CHRNA3
SCHEMBL18704630 0.77 CYP1A2 (0.44) EPHX2
SCHEMBL18711389 0.77 MEN1 (0.48) MEN1ALDH1A1KMT2ACHRNB2CHRNA3
SCHEMBL1008489 0.77 ALDH1A1 (0.35) MEN1ALDH1A1KMT2AHRH3CYP2D6
SCHEMBL2606047 0.77 ALDH1A1 (0.70) MEN1ALDH1A1KMT2ACHRNB2CHRNA3
SCHEMBL619146 0.77 MEN1 (0.48) MEN1ALDH1A1KMT2ACHRNB2CHRNA3
SCHEMBL19429590 0.75 MEN1 (0.47) MEN1ALDH1A1KMT2ACHRNB2CHRNA3
SCHEMBL2603237 0.75 MEN1 (0.47) MEN1ALDH1A1KMT2ACHRNB2CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020238785-A1 METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR 正大天晴药业集团股份有限公司 2020-12-03 WO disclosed
US-9573958-B2 Benzimidazole derivatives as ITK inhibitors PRINCIPIA BIOPHARMA, INC. (US) 2017-02-21 US disclosed